申请人:Knoll Aktiengesellschaft
公开号:US06136825A1
公开(公告)日:2000-10-24
Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; g is 0, 1, 2, 3 or 4; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents an aryl or heteroaryl group, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress and spasticity ##STR1##
化合物的结构式(I)及其药用盐,其中A为亚甲基或--O--; B为亚甲基或--O--; g为0、1、2、3或4;U为一条烷基链,可选择性地被一个或多个烷基取代;Q代表含氮原子的二价基团;T代表芳基或杂环芳基团,具有治疗中枢神经系统疾病的用途,例如抑郁症、焦虑症、精神病(例如精神分裂症)、迟发性运动障碍、帕金森病、肥胖症、高血压、图雷特综合症、功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆症、强迫行为、恐慌发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖型糖尿病、高血糖症、便秘、心律失常、神经内分泌系统障碍、应激和痉挛性。